Annexon shares exploded higher during the regular session following a quiet period of news for the company. While the firm announced the grant of equity inducement awards to six new employees on the evening of October 16, this administrative action is considered neutral and does not account for the significant double-digit move. In the absence of any material company-specific catalysts, the stock appears to have moved in sympathy with broader positive sentiment and high-profile regulatory developments within the biotechnology sector, including recent FDA approvals for other industry players.